Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker BBOT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | James E. Flynn | 3.14M | 3.9% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Management Company, L.P. | 3.14M | 3.9% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Private Design Fund V, L.P. | 1.57M | 2.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Partners, L.P. | 1.57M | 2.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Mgmt V, L.P. | 1.57M | 2.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Mgmt, L.P. | 1.57M | 2.0% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Helix Holdings II LLC | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Global Healthcare GP, LLC | 6.08M | 7.6% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Global Healthcare Master Fund, LP | 6.08M | 7.6% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Private Healthcare GP V, LLC | 5.01M | 6.3% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Private Healthcare Fund V, LP | 5.01M | 6.3% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Private Healthcare GP III, LLC | 4.88M | 6.1% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Private Healthcare Fund III, LP | 4.88M | 6.1% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Bihua Chen | 17.88M | 22.3% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Kenneth Griffin | 2.54M | 3.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Citadel Securities GP LLC | 9,380 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Citadel Securities Group LP | 9,380 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Citadel Securities LLC | 9,380 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Citadel GP LLC | 2.53M | 3.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Citadel Advisors Holdings LP | 2.53M | 3.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Citadel Advisors LLC | 2.53M | 3.2% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Phillip Gross | 1.49M | 1.9% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Robert Atchinson | 1.49M | 1.9% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Adage Capital Management, L.P. | 1.49M | 1.9% | SCHEDULE 13G/A ↗ |
| Sep 3, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Tan Kuangming | 4.37M | 5.5% | SCHEDULE 13G ↗ |
| Sep 3, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | BC Capital Management Limited | 4.37M | 5.5% | SCHEDULE 13G ↗ |
| Sep 3, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | BC General Partner, LP | 4.37M | 5.5% | SCHEDULE 13G ↗ |
| Sep 3, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | BC Global Opportunities IX LP | 4.37M | 5.5% | SCHEDULE 13G ↗ |
| Aug 18, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | James E. Flynn | 4.89M | 6.2% | SCHEDULE 13G ↗ |
| Aug 18, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Management Company, L.P. | 4.89M | 6.2% | SCHEDULE 13G ↗ |
| Aug 18, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Private Design Fund V, L.P. | 2.44M | 3.1% | SCHEDULE 13G ↗ |
| Aug 18, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Partners, L.P. | 2.44M | 3.1% | SCHEDULE 13G ↗ |
| Aug 18, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Mgmt V, L.P. | 2.44M | 3.1% | SCHEDULE 13G ↗ |
| Aug 18, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Deerfield Mgmt, L.P. | 2.44M | 3.1% | SCHEDULE 13G ↗ |
| Aug 18, 2025 | SCHEDULE 13D | BBOT BridgeBio Oncology Therapeutics, Inc. | BridgeBio Pharma, Inc. | 13.88M | 17.5% | SCHEDULE 13D ↗ |
| Aug 18, 2025 | SCHEDULE 13D | BBOT BridgeBio Oncology Therapeutics, Inc. | BridgeBio Pharma LLC | 13.88M | 17.5% | SCHEDULE 13D ↗ |
| Aug 13, 2025 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Bihua Chen | 17.88M | 22.6% | SCHEDULE 13D/A ↗ |
| Aug 13, 2025 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Global Healthcare GP, LLC | 5.95M | 7.5% | SCHEDULE 13D/A ↗ |
| Aug 13, 2025 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Cormorant Global Healthcare Master Fund, LP | 5.95M | 7.5% | SCHEDULE 13D/A ↗ |
| Aug 13, 2025 | SCHEDULE 13D/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Helix Holdings II LLC | 4.53M | 5.7% | SCHEDULE 13D/A ↗ |
| Jul 30, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Israel A. Englander | 897,251 | 4.7% | SCHEDULE 13G/A ↗ |
| Jul 30, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Millennium Group Management LLC | 897,251 | 4.7% | SCHEDULE 13G/A ↗ |
| Jul 30, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Millennium Management LLC | 897,251 | 4.7% | SCHEDULE 13G/A ↗ |
| Jul 30, 2025 | SCHEDULE 13G/A (amended) | BBOT BridgeBio Oncology Therapeutics, Inc. | Integrated Core Strategies (US) LLC | 833,125 | 4.4% | SCHEDULE 13G/A ↗ |
| Jul 24, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Sculptor Special Funding, LP | 967,460 | 5.1% | SCHEDULE 13G ↗ |
| Jul 24, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Sculptor Master Fund, Ltd. | 967,460 | 5.1% | SCHEDULE 13G ↗ |
| Jul 24, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Sculptor Capital Management, Inc. | 967,460 | 5.1% | SCHEDULE 13G ↗ |
| Jul 24, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Sculptor Capital Holding II LLC | 967,460 | 5.1% | SCHEDULE 13G ↗ |
| Jul 24, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Sculptor Capital Holding Corp | 967,460 | 5.1% | SCHEDULE 13G ↗ |
| Jul 24, 2025 | SCHEDULE 13G | BBOT BridgeBio Oncology Therapeutics, Inc. | Sculptor Capital II LP | 967,460 | 5.1% | SCHEDULE 13G ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:58 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances